Uroxatral - Alfuzosinis an active substance, as an antagonist of the α1 adenogenetic receptor, this drug relaxes the muscles of the prostate and the bladder. Used in the treatment of benign prostatic hyperplasia (BPH). Reduces pressure in the urethra and reduces resistance to urine flow, eases urination and eliminates dysuria.

Urispas is an oral antispasmodic drug approved to prevent bladder spasms caused by urethral catheterization, infectious and /or inflammatory diseases of the urogenital system or neurological disorders.